Mackenzie Financial Corp Coherus Bio Sciences, Inc. Transaction History

Mackenzie Financial Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 24, 2023	SELL	$5.89 - $10.52 $151,962 - $271,416	-25,800 Reduced 34.36%	49,283 $337,000
Q4 2022 Feb 14, 2023	BUY	$5.69 - $10.07 $155,866 - $275,847	27,393 Added 57.44%	75,083 $594,000
Q3 2022 Oct 07, 2022	SELL	$7.17 - $13.87 $57 - $110	-8 Reduced 0.02%	47,690 $458,000
Q2 2022 Aug 10, 2022	BUY	$5.86 - $13.23 $82,198 - $185,577	14,027 Added 41.66%	47,698 $345,000
Q1 2022 May 13, 2022	BUY	$10.92 - $16.41 $16,478 - $24,762	1,509 Added 4.69%	33,671 $435,000
Q4 2021 Feb 14, 2022	BUY	$15.81 - $18.99 $508,481 - $610,756	32,162 New	32,162 $513,000

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Mackenzie Financial Corp with notifications on news.